08:01 AM EST, 11/03/2025 (MT Newswires) -- Caribou Biosciences ( CRBU ) said Monday that an ongoing phase 1 clinical trial of its "off-the-shelf" cell therapy vispacabtagene regedleucel in patients with relapsed or refractory B cell non-Hodgkin lymphoma is showing both "efficacy and durability" comparable to other therapies.

The 84-patient study showed an 82% overall response rate, a 64% complete response rate, and a 51% progression-free survival rate at 12 months, the company said.

The company also said that a phase 1 trial evaluating CB-011, an "off-the-shelf" cell therapy, in relapsed or refractory multiple myeloma is advancing into dose expansion, which is expected to begin by the end of this year.

As of Sept. 24, the 12-patient cohort in the study treated with the cell therapy showed a 92% overall response rate and a 75% complete response rate, the company said.

Shares of the company were up more than 39% in recent premarket activity Monday.

Price: 3.97, Change: +0.96, Percent Change: +39.67